WPAI cognitive debriefing projects by target language ...
|WPAI questionnaire cognitive debriefing by target language, as of July 12, 2019 |
|Language |Country |Version |Sample Size |
|Afrikaans |South Africa |WPAI:GH, V2.0 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI+CIQ:AS |5§ |
|Arabic |Egypt |WPAI:GH, V2.1 |5* |
|Arabic |Israel |WPAI:PSO, V2.0 |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Arabic |Jordan |WPAI:GH, V2.0 |5* |
|Arabic |Kuwait |WPAI:MS, V2.1 |5§ |
|Arabic |Lebanon |WPAI:GH, V2.0 |5* |
| | |WPAI:MS, V2.0 |5§ |
|Arabic |UAE |WPAI:GH, V2.0 |5* |
|Arabic |Saudi Arabia |WPAI:GH, V2.0 |5* |
|Belarusian |Belarus |WPAI: Lupus, V2.0 (EDC) |5§ |
|Bengali |India |WPAI:GH, V2.1 |5* |
|Bulgarian |Bulgaria |WPAI:BD |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI:RA, V2.0 |5* |
| | |WPAI:GH, V2.1 |5* |
| | |WPAI:MS, V2.1 |5§ |
|Bosnian |Bosnia |WPAI:CD, V2.0 |5§ |
| | |WPAI:CD-CG, V2.0 |5** |
| | |WPAI:RA, V2.0 |5§ |
|Cebuano |Philippines |WPAI:BD |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Chinese-Simplified |China |WPAI:GH |5* |
| | |WPAI: OA-Knee or Hip, V2.0 |10* |
| | |WPAI:CD, V2.0 |5§ |
| | |WPAI:UC, V2.0 |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|Chinese |Hong Kong |WPAI:DD, V2.0 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Chinese |Malaysia |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
|Chinese |Singapore |WPAI:GH, V1.1 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:NASH, V2.1 |5§ |
| | |WPAI:Uveitis, V2.1 |5§ |
|Chinese |Taiwan |WPAI:LBP, V2.0 |5* |
| | |WPAI: OA-Knee or Hip, V2.0 |5* |
| | |WPAI:Spondyloarthritis, V2.0 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:NASH, V2.2 |5§ |
|Croatian |Croatia |WPAI:GH, V2.0 |5* |
| | |WPAI:DD, V2.0 |5* |
|Czech |Czech Republic |WPAI:CD-CG, V2.0 |5* |
| | |WPAI:CD |5* |
| | |WPAI:GH |5* |
| | |WPAI:ASTHMA, V2.0 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI+CIQ:AS (EDC) |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:NASH, V2.5 |5§ |
|Danish |Denmark |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:GH |5* |
| | |WPAI:PSO. V2.0 |5* |
| | |WPAI:Spondyloarthritis, V2.0 |5* |
| | |WPAI:NASH, V2.0 |5§ |
|Dutch |Belgium |WPAI:Spondyloarthritis, V2.0 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:NASH, V2.3 |5§ |
| | |WPAI:Hypoparathyroidism, V2.2 |5§ |
|Dutch |Netherlands |WPAI:CD-CG, V2 |6* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:NASH, V2.0 |5§ |
| | |WPAI:Hypoparathyroidism, V2.0 |5§ |
|English |Australia |WPAI:Menopause, V2 |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:PsA, V2.0 |5* |
| | |WPAI:NASH, V2.0 |5§ |
|English |Canada |WPAI:AA-IVRS |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.0 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|English |India |WPAI:GH |5* |
| | |WPAI:ASTHMA, V2 |5* (needs more |
| | | |testing) |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|English |Israel |WPAI:GH, V1 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|English |Malaysia |WPAI: Lupus, V2.0 (EDC) |5§ |
|English |New Zealand |WPAI:Menopause, V2 |5§ |
| | |WPAI:Lupus, V2.0 (EDC) |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|English |Philippines |WPAI:Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
|English |Singapore |WPAI:GH, V1 |5* |
| | |WPAI:Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI:NASH, V2.0 |5§ |
|English |South Africa |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI+CIQ:AS, V1.1 |5§ |
|English |Thailand |WPAI: Lupus, V2.0 (EDC) |5§ |
|English |UK |WPAI:AA-IVRS |5* |
| | |WPAI:FMS-Pain |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:DD, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.0 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI+CIQ:AS, V1.1 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|English |US |WPAI:GH |30* |
|Estonian |Estonia |WPAI:PsA, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5* |
| | |WPAI+CIQ:AS |5§ |
|Farsi |US |WPAI:GH, V2.0 |5* |
|Filipino |Philippines |WPAI:GH |5* |
| | |WPAI:BD |5§ |
|Finnish |Finland |WPAI+CIQ:AS |5* |
| | |WPAI:GH |5* |
| | |WPAI:RA, V2 |5* |
| | |WPAI:GH, V2.0 |5* |
|Flemish |Belgium |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:RA, V2.1 |5§ |
|French |Belgium |WPAI:AA-IVRS |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI+CIQ:AS (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:NASH, V2.3 |5§ |
| | |WPAI: Hypoparathyroidism, V2.3 |5§ |
|French |Canada |WPAI:CD-CG, V2 |5* |
| | |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5* |
| | |WPAI:NASH, V2.2 |5§ |
|French |France |WPAI:CD-CG, V2 |5* |
| | |WPAI:FMS-Pain, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:NASH, V2.2 |5§ |
|French |Switzerland |WPAI+CIQ:AS, V1.1 |5§ |
| | |WPAI:GH, V2.2 |5* |
| | |WPAI:NASH, V2.3 |5§ |
|French |Tunisia |WPAI: Lupus, V2.0 (EDC) |5§ |
|Galician |Spain |WPAI:NASH, V2.0 |5§ |
|Georgian |Georgia |WPAI:NASH, V2.1 |5§ |
|German |Austria |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI: Hypoparathyroidism, V2.1 |5§ |
|German |Belgium |WPAI:RA, V2.0 |5§ |
| | |WPAI:GH, V2.0 |5* |
|German |Germany |WPAI:AA_IVRS |5* |
| | |WPAI+CIQ:AA, V2 |5* |
| | |WPAI:FMS-pain |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:DD, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI:GH, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:PsA, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|German |Switzerland |WPAI+CIQ:AS |5* |
| | |WPAI:RA, V2.0 |5* |
| | |WPAI:GH, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Greek |Greece |WPAI:CD |5* |
| | |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:GH, V2.2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:PsA, V2.2 |5* |
| | |WPAI:NASH, V2.2 |5§ |
|Gujarati |India |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Hebrew |Israel |WPAI:AA-IVRS |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:NASH, V2.0 |5§ |
|Hindi |India |WPAI:GH |5* |
| | |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Hungarian |Hungary |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:CD |5* |
| | |WPAI:ASTHMA, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:NASH, V2.2 |5§ |
|Icelandic |Iceland |WPAI:CD |5* |
| | |WPAI:GH, V2.1 |5* |
|Italian |Italy |WPAI:FMS-Pain, V2 |5* |
| | |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:CD-CG, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:NASH, V2.4 |5§ |
|Italian |Switzerland |WPAI:GH, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Japanese |Japan |WPAI:GH, V2 |5* |
| | |WPAI:PSO, V2.1 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:CD, V2.1 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI:GERD, V2.0 |5§ |
|Kannada |India |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Kazakh |Kazakhstan |WPAI:RA, V2.0 |5§ |
|Korean |Korea |WPAI:GH |5* |
| | |WPAI:ASTHMA, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
|Latvian |Latvia |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.0 |5§ |
| | |WPAI:PsA, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Lithuanian |Lithuania |WPAI:BD |5§ |
| | |WPAI:PSO, V2.1 |5§ |
| | |WPAI:RA, V2.1 |5* |
|Macedonian |Macedonia |WPAI: Lupus, V2.0 (EDC) |5§ |
|Malay |Malaysia |WPAI:BD |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.1 |5* |
|Malay |Singapore |WPAI:GH, V1 |5* |
| | |WPAI:GH, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
| | |WPAI: Uveitis, V2.1 |5§ |
|Malayalam |India |WPAI:GH |5* |
| | |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Mandarin |Malaysia |WPAI:BD |5§ |
|Mandarin |Taiwan |WPAI:BD |5§ |
|Marathi |India |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Norwegian |Norway |WPAI:AA-IVRS |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:GH, V2.1 |5* |
|Polish |Poland |WPAI:CD-CG, V2 |5* |
| | |WPAI:AA-IVRS |5* |
| | |WPAI:CD |6* |
| | |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI+CIQ:AS (EDC) |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI+CIQ:AS |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:NASH, V2.3 |5§ |
|Portuguese |Portugal |WPAI:CD |5* |
| | |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:IBD, V2 |5* |
| | |WPAI:Hepatitis C, V2.0 |5* |
| | |WPAI:GH, V2.1 |5* |
| | |WPAI:NASH, V2.1 |5§ |
| | |WPAI: Hypoparathyroidism, V2.2 |5§ |
|Portuguese |Brazil |WPAI:ASTHMA, V2 |5* (needs more |
| | | |testing) |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:MS V2.2 |5§ |
| | |WPAI:NASH, V2.2 |5§ |
|Punjabi |India |WPAI:GH |5* |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Romanian |Romania |WPAI:BD |5§ |
| | |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:NASH, V2.1 |5§ |
|Russian |Belarus |WPAI: Lupus, V2.0 (EDC) |5§ |
|Russian |Estonia |WPAI:PsA, V2.1 |5§ |
|Russian |Georgia |WPAI:NASH, V2.0 |5§ |
|Russian |Israel |WPAI:GH, V1 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:NASH, V2.4 |5§ |
|Russian |Latvia |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.0 |5§ |
| | |WPAI:PsA, V2.0 |5* |
| | |WPAI:NASH, V2.1 |5§ |
|Russian |Russia |WPAI+CIQ:AS |5* |
| | |WPAI:GH, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.0 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
|Russian |Ukraine |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
|Serbian |Serbia |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5* |
|Sesotho |South Africa |WPAI: Lupus, V2.0 (EDC) |5§ |
|Slovak |Slovakia |WPAI:CD |5* |
| | |WPAI:ASTHMA, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:RA, V2.1 |5* |
| | |WPAI:GH, V2.2 |5* |
|Slovene |Slovenia |WPAI:CD, V1.1 |5* |
| | |WPAI:MS, V2.1 |5§ |
| | |WPAI:NASH, V2.1 |5§ |
|Spanish |Argentina |WPAI:Menopause, V2 |5§ |
| | |WPAI:ASTHMA, V2 |5* (needs more |
| | | |testing) |
| | |WPAI:DD, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI:PSO, V2.1 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
|Spanish |Chile |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI+CIQ:AS |5§ |
| | |WPAI:PSO, V2.0 |5§ |
|Spanish |Colombia |WPAI:ASTHMA, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Spanish |Ecuador |WPAI: Lupus, V2.0 (EDC) |5§ |
|Spanish |Guatemala |WPAI: Lupus, V2.0 (EDC) |5§ |
|Spanish |Mexico |WPAI:GH |5* |
| | |WPAI:LBP, V2.0 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI+CIQ:AS |5§ |
| | |WPAI: SpA, V2.0 |5§ |
| | |WPAI:GH, V2.1 |5* |
|Spanish |Peru |WPAI:ASTHMA, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:NASH, V2.0 |5§ |
|Spanish |Puerto Rico |WPAI:ASTHMA, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:NASH, V2.2 |5§ |
|Spanish |Spain |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:PSO, V2.0 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:NASH, V2.1 |5§ |
| | |WPAI: Hypoparathyroidism, V2.1 |5§ |
|Spanish |US |WPAI:CD-CG, V2 |5* |
| | |WPAI:GH |30* |
| | |WPAI:ASTHMA, V2 |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI:GERD-SDQ, V2 |5* |
| | |WPAI:LBP, V2 |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PSO, V2.1 |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI+CIQ:AS (EDC) |5§ |
| | |WPAI:PsA, V2.1 |5§ |
| | |WPAI+CIQ:AS, V1.1 |5§ |
| | |WPAI: SpA, V2.1 |5§ |
| | |WPAI:CRPC, V2.2 |5§ |
| | |WPAI:CRPC-CG, V2.2 |5** |
| | |WPAI:NASH, V2.2 |5§ |
| | |WPAI:MS, V2.2 |5§ |
|Swedish |Finland |WPAI:Spondyloarthritis, V2 |5* |
| | |WPAI+CIQ:AS |5§ |
| | |WPAI:GH, V2.0 |5* |
|Swedish |Sweden |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:Menopause, V2 |5§ |
| | |WPAI:GH, V2.0 |5* |
| | |WPAI:RA, V2.1 |5* |
|Tagalog |Philippines |WPAI: Lupus, V2.0 (EDC) |5§ |
|Tamil |India |WPAI:GH |5* |
| | |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Tamil |Malaysia |WPAI:BD |5§ |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Tamil |Singapore |WPAI:NASH, V2.0 |5§ |
|Telugu |India |WPAI:GH |5* |
| | |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Thai |Thailand |WPAI:BD |5§ |
| | |WPAI:GH, V2 |5* |
| | |WPAI: OA-Knee or Hip, V2.0 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Turkish |Turkey |WPAI:AA-IVRS |5* |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:PsA, V2.0 |5§ |
|Ukrainian |Ukraine |WPAI:BD |5§ |
| | |WPAI+CIQ:AS |5* |
| | |WPAI:DD, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
| | |WPAI:RA, V2.1 |5§ |
| | |WPAI:PsA, V2.0 |5§ |
| | |WPAI: SpA, V2.0 |5§ |
|Urdu |India |WPAI:GH |5* |
| | |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|Vietnamese |Vietnam |WPAI:GH, V2 |5* |
|Xhosa |South Africa |WPAI: Lupus, V2.0 (EDC) |5§ |
|Zulu |South Africa |WPAI:GH, V2 |5* |
| | |WPAI: Lupus, V2.0 (EDC) |5§ |
|*Subjects recruited from the general population and were selected to be diverse in age, gender and education. |
|§ Subjects recruited from patient population with the target disease/ condition. |
|** Subjects recruited from caregivers of target patient disease/ condition. |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- keohane d
- idea for using the eisenhower documents for a paper for
- wpai by target language reilly associates
- wpai cognitive debriefing projects by target language
- work stream 1 transparency welcome to the iasc iasc
- council for democratic
- varaždin edc citizenship site
- eoi template final asf
- bibliografia e fontes
- company profile engels info mol logistics
Related searches
- projects by students for students
- social cognitive theory by bandura
- cognitive milestones by age
- cognitive and language development milestones
- target solutions by vector solutions
- free english books language step by step
- language development stages by age
- target asset allocation by age
- cognitive development stages by age
- definition of language by scholars
- receptive language skills by age
- cognitive psychology by goldstein